17 10, 2024

ClearB Therapeutics announces a license and collaboration with Adjuvance Technologies to access a novel saponin adjuvant, TQL-1055, and upcoming poster presentations of preclinical chronic hepatitis B data at AASLD 2024.

ClearB Therapeutics announces a license and collaboration with Adjuvance Technologies to access a novel saponin adjuvant, TQL-1055, and upcoming poster presentations of pre-clinical chronic hepatitis B data at AASLD 2024. CONCORD, MA, 17 OCTOBER 2024 — ClearB Therapeutics, Inc., a company developing therapeutic vaccines designed to [...]

12 10, 2023

ClearB Therapeutics Announces First Patient Dosed in a Phase 1b First in Human Study of CLB-3000 and a Presentation at AASLD 2023 of Preclinical data both for the Treatment of Chronic Hepatitis B Infection

ClearB Therapeutics Announces First Patient Dosed in a Phase 1b First in Human Study of CLB-3000 and a Presentation at AASLD 2023 of Preclinical data both for the Treatment of Chronic Hepatitis B Infection October 12, 2023 07:00 AM Eastern Daylight Time CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, [...]

15 06, 2022

ClearB Therapeutics Announces Acceptance of Abstract Highlighting Pre-Clinical Chronic Hepatitis B Data as a Poster Presentation at EASL 2022

ClearB Therapeutics Announces Acceptance of Abstract Highlighting Pre-Clinical Chronic Hepatitis B Data as a Poster Presentation at EASL 2022 June 15, 2022 09:16 AM Eastern Daylight Time CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure of hepatitis B, [...]

21 06, 2021

ClearB Therapeutics Announces Acceptance of Abstract Highlighting New Pre-Clinical Hepatitis B Data as a Poster Presentation at EASL 2021

June 21, 2021 ClearB Therapeutics Announces Acceptance of Abstract Highlighting New Pre-Clinical Hepatitis B Data as a Poster Presentation at EASL 2021 CONCORD, Mass. & MELBOURNE, Australia--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its abstract [...]